Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

Targeted Therapy (Investigational) (36)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Elimusertib	DNA Damage Response Inhibitor	Solid Tumour
Molecule Elimusertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Gartisertib	DNA Damage Response Inhibitor	Solid Tumour
Molecule Gartisertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Selumetinib Sulfate	DNA Damage Response Inhibitor	Solid Tumour
Molecule Selumetinib Sulfate Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Tunlametinib	DNA Damage Response Inhibitor	Solid Tumour
Molecule Tunlametinib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Ianalumab	Targeted Protein Degrader	Hematologic
Molecule Ianalumab Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
CFT7455 (Cereblon Degrader)	Targeted Protein Degrader	Hematologic
Molecule CFT7455 (Cereblon Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
BGB-16673 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule BGB-16673 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-2127 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule NX-2127 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-5948 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule NX-5948 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
Volasertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Volasertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Rigosertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Rigosertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
BI-847325	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule BI-847325 Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor

Elimusertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Gartisertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Selumetinib Sulfate Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Tunlametinib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Ianalumab Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
CFT7455 (Cereblon Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
BGB-16673 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-2127 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
NX-5948 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
Volasertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Rigosertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
BI-847325 Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor

‹ 1 2 3 ›

Product Range

Company

Global Network

Products

Elimusertib

Gartisertib

Selumetinib Sulfate

Tunlametinib

Ianalumab

CFT7455 (Cereblon Degrader)

BGB-16673 (BTK Degrader)

NX-2127 (BTK Degrader)

NX-5948 (BTK Degrader)

Volasertib

Rigosertib

BI-847325